{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-024292","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.440721+00:00","generated_at":"2026-06-14T14:46:50.746927+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca reports early data on ERAS-007 combos: 40% response in BRAFm CRC; stops palbociclib combo in KRASm tumors","bullets":["ERAS-007 + encorafenib + cetuximab in BRAF V600E CRC: 40% response (2/5) at 100mg BID-QW, 29% overall across doses.","Combination generally well-tolerated with mostly low-grade AEs; one DLT (Grade 3 macular edema) at highest dose.","ERAS-007 + palbociclib showed no clinical activity in KRAS/NRAS mutant CRC and KRASm PDAC; company will not pursue combo.","Additional Phase 1b HERKULES-3 data in BRAF-mutated CRC expected between H2 2023 and H1 2024.","PK exposures of ERAS-007, encorafenib, cetuximab comparable to monotherapy, no significant drug-drug interactions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-024292","json":"https://secwatch.observer/filing/0000950170-23-024292.json","markdown":"https://secwatch.observer/filing/0000950170-23-024292.md","text":"https://secwatch.observer/filing/0000950170-23-024292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/0000950170-23-024292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/eras-20230525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:46:50.746927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}